215099-43-7

Basic information

• Product Name: 2-Pyridineethanamine,5-amino-(9CI)
• Synonyms: 2-Pyridineethanamine,5-amino-(9CI);2-PyridineethanaMine, 5-aMino-
• CAS NO: 215099-43-7
• Molecular Formula: C7H11N3
• Molecular Weight: 137.18234
• Product Categories: PYRIDINE
• Mol File: 215099-43-7.mol

Chemical Properties

• Boiling Point: 310.0±27.0 °C(Predicted)
• Appearance: /
• Density: 1.129±0.06 g/cm3(Predicted)
• PKA: 9.03±0.10(Predicted)
• CAS DataBase Reference: 2-Pyridineethanamine,5-amino-(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Pyridineethanamine,5-amino-(9CI)(215099-43-7)
• EPA Substance Registry System: 2-Pyridineethanamine,5-amino-(9CI)(215099-43-7)

Safety Data

• Hazardous Substances Data: 215099-43-7(Hazardous Substances Data)

Upstream product

• 4548-45-2 2-chloro-5-nitropyridine 
• 914223-27-1 tert-butyl 2-cyano-2-(5-nitropyridin-2-yl)acetate 
• 123846-66-2 2-(5-nitropyridin-2-yl)acetonitrile 
• 883993-15-5 2-(5-amino-2-pyridyl)acetonitrile 

Relevant articles and documents

COMPOUNDS FOR MODULATING IL-17

The invention relates generally to compounds and their therapeutic use. More particularly, the invention relates to compounds that modulate the activity of IL-17 and/or are useful in the treatment of medical conditions, such as inflammatory diseases and other IL-17-associated disorders.

Epoxysuccinamide derivative or salt thereof

PCT No. PCT/JP98/01778 Sec. 371 Date Dec. 17, 1998 Sec. 102(e) Date Dec. 17, 1998 PCT Filed Apr. 17, 1998 PCT Pub. No. WO98/47887 PCT Pub. Date Oct. 29, 1998The invention relates an epoxysuccinamide derivative represented by a formula (I): wherein R1 represents a hydrogen atom, an alkyl or aminoalkyl group, R2 represents an aminoalkyl group which May be substituted, an aryl group which may be substituted, a heterocyclic group which may be substituted, an aralkyl group which may be substituted, or an alkyl group substituted by a heterocyclic ring which may be substituted, or R1 and R2 may form a nitrogen-containing heterocyclic ring, which may be substituted, together with the adjacent nitrogen atoms, and R3 and R4 are the same or different from each other and independently represent a hydrogen atom, or an alkyl or aralkyl group, or a salt thereof, a preparation process thereof, and a medicine comprising such a derivative or salt as an active ingredient. This compound has a specific inhibitory activity for cathepsin L and family enzymes thereof, and is useful as an agent for preventing and treating metabolic osteopathy such as osteoporosis and hypercalcemia.